Rosetta Genomics Announces Data Demonstrating the Ability of miRview mets(2) to Identify Tissue of Origin in Cancer of Unknown Primary Presented at ASCO 2011

Rosetta Genomics ROSG announces that data presented at the American Society of Clinical Oncology 2011 showed the Company's miRview® mets(2) test accurately identified the tissue of origin in Cancer of Unknown Primary patients in a post-marketing validation study. Findings from a study highlighting the clinical utility of miRview® mets(2) in identifying tissue of origin in CUP patients were presented at ASCO in a poster entitled "A second generation microRNA-based assay for diagnosing tumor tissue origin."